2. Academic Validation
  3. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress

  • Curr Atheroscler Rep. 2023 Dec;25(12):965-978. doi: 10.1007/s11883-023-01164-5.
Kartik Gupta 1,  Colin Hinkamp 2,  Tyler Andrews 3,  Chelsea Meloche 2,  Abdul Mannan Khan Minhas 4,  Leandro Slipczuk 5,  Elizabeth Vaughan 4 6,  Fatima Zohra Habib 7,  Sana Sheikh 7,  Dinesh Kalra 8,  Salim S Virani 9 10 11
Affiliations

Affiliations

  • 1 Division of Cardiovascular Diseases, Henry Ford Hospital, Detroit, MI, USA.
  • 2 Division of Cardiovascular Diseases, The Texas Heart Institute, Houston, TX, USA.
  • 3 Department of Medicine, Henry Ford Hospital, Detroit, MI, USA.
  • 4 Section of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • 5 Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
  • 6 Department of Internal Medicine, Medical Branch, University of Texas, Galveston, TX, USA.
  • 7 Section of Cardiology, Department of Medicine, The Aga Khan University, Karachi, Pakistan.
  • 8 Rudd Heart & Lung Center, University of Louisville School of Medicine, Louisville, KY, USA.
  • 9 Division of Cardiovascular Diseases, The Texas Heart Institute, Houston, TX, USA. salim.virani@aku.edu.
  • 10 Section of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. salim.virani@aku.edu.
  • 11 Section of Cardiology, Department of Medicine, The Aga Khan University, Karachi, Pakistan. salim.virani@aku.edu.
PMID: 37975955 DOI: 10.1007/s11883-023-01164-5
Abstract

Purpose of review: To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 European Society of Cardiology (ESC) congress.

Recent findings: The NATURE-PARADOX was a naturally randomized trial that used genetic data from the UK Biobank registry to create "cumulative exposure to low-density lipoprotein-cholesterol (LDL-C)" biomarker and evaluate its association with major CV events regardless of plasma LDL-C levels or age. Safety and efficacy data of inclisiran, a PCSK9-interfering mRNA (PCSK9i) administered subcutaneously twice annually, were presented. Data on two new PCSK9is were presented, recaticimab, an oral drug, and lerodalcibep, a subcutaneous drug with a slightly different architecture than currently available PSCK9is. A phase 1 trial on muvalaplin, an oral lipoprotein (a) inhibitor, was presented. An atherosclerotic CV disease (ASCVD) risk prediction algorithm for the Asian population using SCORE2 data was presented. Long-term follow-up of patients enrolled in the CLEAR outcomes trial showed sustained and more significant ASCVD risk reduction with bempedoic acid in high-risk patients. The late-breaking clinical science at the 2023 congress of the ESC extends the known safety and efficacy data of a PCSK9i with the introduction of new drugs in this class. Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine.

Keywords

CLEAR; DANCAVAS; ESC; INTERSPIRE; NATURE-PARADOX; OCEAN(a); PCSK9; SCORE-2 ASIA.

Figures
Products